

Apéndice Online

Tabla I: Estrategia de búsqueda desarrollada para Medline

Base de datos: Medline (In-Process & Other Non-Indexed Citations and MEDLINE 1946 a la actualidad)

Plataforma de búsqueda: OvidSP

Fecha de búsqueda: 30 de Noviembre 2015

Límite temporal: 1995 - actualidad

#	Término de búsqueda	Hits
1	exp Cancer of Cervix/	63255
2	((cervi\$ or uter\$) adj3 (cancer\$ or neoplasm\$ or neoplasia or tumour\$ or tumor\$ or carcinoma or adenocarcinoma or malingnan\$ or metasta\$)).mp.	124390
3	Or/1-2	124390
4	exp "Head and Neck Neoplasms"/	261351
5	exp Oropharyngeal Neoplasms/	6600
6	((head\$ or neck\$ or oro\$ \$pharyn\$) adj3 (cancer\$ or neoplasm\$ or neoplasia or tumour\$ or tumor\$ or carcinoma or adenocarcinoma or malingnan\$ or metasta\$)).mp.	60946
7	or/4-6	271413
8	((precancer\$ or pre-cancer\$ or neoplas\$ or dysplasia or lesion\$ or premalignan\$ or malignan\$ or cancer\$ or carcinoma\$ or intraepithelial) adj3 (cervi\$ or vulva\$ or vagina\$ or peni\$ or anal or anus)).mp.	87212
9	((precancer\$ or pre-cancer\$ or dysplasia or premalignan\$ or intraepithelial) adj3 lesion\$).mp.	10090
10	(cin or cin2* or cin3* or cin1* or VAIN or VAIN1* or VAIN2* or VAIN3* or VIN or VIN1* or VIN2* or VIN3* or PeIN or PeIN1* or PeIN2* or PeIN3* or AIN or AIN1* or AIN2* or AIN3*).tw.	9007
11	exp Precancerous Conditions/	38860
12	exp cervical intraepithelial neoplasia/	8297
13	exp uterine cervical dysplasia/	3765
14	vaginal intraepithelial neoplasia {Including Related Terms}	687
15	penile intraepithelial neoplasia {Including Related Terms}	70
16	anal intraepithelial neoplasia {Including Related Terms}	2987
17	vulvar intraepithelial neoplasia {Including Related Terms}	1017
18	Or/8-17	151037
19	exp Vaginal Neoplasms/	4854
20	(vagin\$ adj3 (cancer\$ or neoplasm\$ or neoplasia or tumour\$ or tumor\$ or carcinoma or adenocarcinoma or malingnan\$ or metasta\$)).mp.	6195
21	Or/19-20	6195
22	exp vulva cancer/	7307
23	(vulv\$ adj3 (cancer\$ or neoplasm\$ or neoplasia or tumour\$ or tumor\$ or carcinoma or adenocarcinoma or malingnan\$ or metasta\$)).mp.	8357
24	Or/22-23	8357

25	exp Anus Neoplasms/	5264
26	((anus or anal) adj3 (cancer\$ or neoplasm\$ or neoplasia or tumour\$ or tumor\$ or carcinoma or adenocarcinoma or malingnan\$ or metasta\$)).mp.	6575
27	or/25-26	6575
28	exp Penile Neoplasms/	4747
29	(peni\$ adj3 (cancer\$ or neoplasm\$ or neoplasia or tumour\$ or tumor\$ or carcinoma or adenocarcinoma or malingnan\$ or metasta\$)).mp.	5473
30	or/28-29	5473
31	exp Verruca/	9087
32	exp Condylomata Acuminata/	4827
33	(((\$genit\$ or ana\$ or ano\$ or vener\$) adj3 wart\$).mp.	2805
34	or/31-33	10386
35	HPV.tw.	29575
36	(papillomavirus or (papilloma adj virus)).tw.	31752
37	(VPH or HPV).mp.	30166
38	exp papillomaviridae/	26988
39	exp Papilloma/	11233
40	exp Papillomatosis/	11233
41	papilloma\$.mp.	57416
42	or/35-41	60502
43	exp Epidemiologic Studies/	1859416
44	exp prevalence/	215966
45	exp incidence/	196334
46	((epidem* or preval* or inciden*) adj3 (papilloma or papiloma or VPH or HPV)).tw.	3668
47	(epidem\$ or preval\$ or inciden\$).mp.	1574862
48	epidemiologic studies/	6459
49	("prevalence study" or "incidence study" or "prevalence studies" or "incidence studies" or "transversal studies" or "transversal study").mp.	6232
50	or/43-49	3015289
51	Economics/	27221
52	"costs and cost analysis"/	43729
53	Cost allocation/	1972
54	Cost-benefit analysis/	65229
55	Cost control/	20846
56	Cost savings/	9582
57	Cost of illness/	20264

58	Cost sharing/	2097
59	"deductibles and coinsurance"/	1497
60	Medical savings accounts/	499
61	Direct service cost/	1082
62	Health care costs/	30415
63	Drug costs/	13359
64	Employer health costs/	1076
65	Hospital costs/	8616
66	Health expenditures/	15022
67	Capital expenditures/	1967
68	Value of life/	5533
69	exp economics, hospital/	20937
70	cost effectiveness analys\$.mp.	8012
71	exp economics, medical/	14109
72	Economics, nursing/	3957
73	Economics, pharmaceutical/	2651
74	exp "fees and charges"/	28027
75	exp budgets/	12637
76	(low adj cost).mp.	31126
77	(economic\$ and (evaluat\$ or analys\$ or model\$)).mp.	117692
78	(high adj cost).mp.	9388
79	(health?care adj cost\$.mp.	5854
80	(fiscal or funding or financial or finance).tw.	97599
81	cost benefit analys\$.mp.	66771
82	(cost adj estimate\$.mp.	1622
83	(cost adj variable).mp.	39
84	economics, pharmaceutical/	2651
85	(unit adj cost\$.mp.	1786
86	(pharmaco adj economic\$.mp.	327
87	health economic\$.mp.	5128
88	economic aspect\$.mp.	2011
89	(cba or cea or cua).mp.	44931

90	(econom\$ or cost\$ or pric\$ or pharmacoeconomic\$).mp.	719448
91	cost minimi?ation analys\$.mp.	537
92	(cost\$ or (cost\$ adj2 (effective\$ or utili\$ or benefit\$ or minimi\$ or stud\$ or effic\$ or effect\$))).mp.	501021
93	cost utili\$ analys\$.mp.	1938
94	cost utili\$ analys\$.mp.	1938
95	cost of illness.mp.	20833
96	economics, nursing/	3957
97	exp economics, medical/	14109
98	exp economics, hospital/	20937
99	(economic\$ or pharmacoeconomic\$ or price\$ or pricing).tw.	203019
100	or/51-99	855805
101	diagnos\$.ti,ab,hw.	2201218
102	guideline.ti,ab,pt,xm.	46369
103	guideline\$.ti,ab.	223179
104	consensus.ti,ab,pt,xm.	114653
105	consen\$.ti,ab.	170503
106	patient held record.mp.	33
107	exp Medical Records/	94424
108	critical pathways/ or patient selection/ or point-of-care systems/	67771
109	exp professional-patient relations/ or nurse-patient relations/	125899
110	exp clinical pathway/	5140
111	exp clinical protocol/	137439
112	exp consensus development conference/	10138
113	exp consensus development conferences as topic/	2414
114	critical pathways/	5140
115	exp guideline/	27463
116	guidelines as topic/	33811
117	exp practice guideline/	21077
118	practice guidelines as topic/	90232
119	health planning guidelines/	3997
120	(standards or guideline or guidelines).ti.	75151
121	(position statement* or policy statement* or practice parameter* or best practice*).ti,ab.	18710

122	(guideline or practice guideline or consensus development conference or consensus development conference, NIH).pt.	35557
123	((practice or treatment*) adj guideline*).ab.	19156
124	(CPG or CPGs).ti.	4791
125	consensus*.ti.	16531
126	consensus*.ab. /freq=2	16721
127	((critical or clinical or practice) adj2 (path or paths or pathway or pathways or protocol)).ti,ab.	13681
128	recommenda*.ti.	27171
129	exp treatment/	3613185
130	(care adj2 (standard or path or paths or pathway or pathways or map or maps or plan or plans)).ti,ab.	34561
131	(algorithm* adj2 (screening or examination or test or tested or testing or assessment* or diagnosis or diagnoses or diagnosed or diagnosing)).ti,ab.	4825
132	(algorithm* adj2 (pharmacotherap* or chemotherap* or chemotreatment* or therap* or treatment* or intervention*)).ti,ab.	6055
133	exp prescriptions/	27786
134	exp diagnosis/	6987342
135	or/101-134	10333527
136	(Spanish or spain or espagne or espana or spagna or spanien or iberia\$).in,hw,mp.	384067
137	(catalunya or catalonia or catalogne or cataluna or catala or barcelon\$ or tarragona or lleida or lerida or girona or gerona or sabadell or hospitalet or \$hospitalet (Valencia\$ or castello\$ or alacant or alicant\$)).in,hw,mp.	133588
138	(Murcia or (cartagen\$ not indias) or (andalu\$ or sevilla\$ or granad\$ or huelva or almeria or cadiz or jaen or malaga or (cordoba not argentin\$)) or (extremadura or caceres or badajoz or madrid) or (castilla or salamanca or zamora or valladolid or segovia or soria or palencia or avila or burgos) or (leon not (france or clermont or rennes or lyon or USA or mexic\$))).in,hw,mp.	186112
139	(galicia or gallego or compostela or vigo or corun\$ or ferrol or orense or ourense or pontevedra or lugo or (oviedo or gijon or asturia\$) or (cantabr\$ or santander) or (vasco or euskadi or basque or bilbao or bilbo or donosti\$ or san sebastian or vizcaya or bizkaia or guipuzcoa or gipuzkoa or alava or araba or vitoria or gasteiz) or (navarr\$ or nafarroa or pamplona or iruna or irunea) or (logron\$ or rioj\$) or (aragon\$ or zaragoza or teruel or huesca)).in,hw,mp.	85825
140	(mancha or ciudad real or albacete or cuenca or (toledo not (ohio or us or usa or OH)) or (guadalajara not mexic\$) or (balear\$ or mallorca or menorca or Ibiza or eivissa) or (palmas or lanzarote or canari\$ or tenerif\$) or (ceuta or melilla) or ((osasunbide\$ or osakidetza or insalud or sergas or catsalut or sespa or osasunbidea or imsalud or sescam or ib) adj1 salud)).in,hw,mp.	21803
141	or/136-140	443381
142	3 and 42 and 50 and 141	289
143	3 and 100 and 141	125
144	3 and 42 and 135 and 141	301
145	or/142-144	475
146	7 and 42 and 50 and 141	59
147	7 and 100 and 141	98
148	7 and 42 and 135 and 141	93
149	or/146-148	202
150	18 and 42 and 50 and 141	338

151	18 and 100 and 141	133
152	18 and 42 and 135 and 141	362
153	or/150-152	554
154	21 and 42 and 50 and 141	15
155	21 and 100 and 141	8
156	21 and 42 and 135 and 141	15
157	or/154-156	19
158	24 and 42 and 50 and 141	17
159	24 and 100 and 141	10
160	24 and 42 and 135 and 141	24
161	or/158-160	30
162	27 and 42 and 50 and 141	43
163	27 and 100 and 141	11
164	27 and 42 and 135 and 141	35
165	or/162-164	51
166	30 and 42 and 50 and 141	22
167	30 and 100 and 141	7
168	30 and 42 and 135 and 141	22
169	or/166-168	28
170	34 and 42 and 50 and 141	37
171	34 and 100 and 141	9
172	34 and 42 and 135 and 141	38
173	or/170-172	53
174	145 or 149 or 153 or 157 or 161 or 165 or 169 or 173	780
175	limit 174 to (yr="1995 -Current" and (english or spanish))	720

Tabla II. Estrategia de búsqueda desarrollada para Embase

Base de datos: Embase (1988 a 2015 - semana 46)

Plataforma de búsqueda: OvidSP

Fecha de búsqueda: 30 de Noviembre 2015

Límite temporal: 1995 - actualidad

#	Término de búsqueda	Hits
1	exp cervical cancer/	61951
2	exp uterine cervical neoplasms/	71519
3	exp Cervix Neoplasms/	71519
4	exp Uterine Cervical Cancer/	61951
5	((cervi\$ or uter\$) adj3 (cancer\$ or neoplasm\$ or neoplasia or tumour\$ or tumor\$ or carcinoma or adenocarcinoma or malingnan\$ or metasta\$)).mp.	108562
6	or/1-5	108562
7	exp "Head and Neck Neoplasms"/	185694
8	exp "Head and Neck Cancer"/	103045
9	exp Head Cancer/	1290
10	exp Neck Cancer/	2897
11	exp Oropharyngeal Neoplasms/	7536
12	exp Oropharyngeal Cancer/	6250
13	exp Oropharynx Cancer/	6250
14	((head\$ or neck\$ or oro\$ \$pharyn\$) adj3 (cancer\$ or neoplasm\$ or neoplasia or tumour\$ or tumor\$ or carcinoma or adenocarcinoma or malingnan\$ or metasta\$)).mp.	71606
15	or/7-14	196947
16	((precancer\$ or pre-cancer\$ or neoplas\$ or dysplasia or lesion\$ or premalignan\$ or malignan\$ or cancer\$ or carcinoma\$) adj3 (cervi\$ or vulva\$ or vagina\$ or peni\$ or anal or anus)).mp.	103730
17	((precancer\$ or pre-cancer\$ or dysplasia or premalignan\$) adj3 lesion\$).mp.	11851
18	(cin or cin2* or cin3* or cin1* or VAIN or VAIN1* or VAIN2* or VAIN3* or VIN or VIN1* or VIN2* or VIN3* or PeIN or PeIN1* or PeIN2* or PeIN3* or AIN or AIN1* or AIN2* or AIN3*).tw.	17514
19	vulvar intraepithelial neoplasia {Including Related Terms}	1455
20	vaginal intraepithelial neoplasia {Including Related Terms}	11705
21	anal intraepithelial neoplasia {Including Related Terms}	4227
22	penile intraepithelial neoplasia {Including Related Terms}	108
23	exp cervical intraepithelial neoplasia/	11225

24	exp uterine cervical dysplasia/	3761
25	or/16-24	100660
26	exp Vaginal Neoplasms/	3917
27	exp Vagina Cancer/	2540
28	exp Vaginal cancer/	2540
29	(vagin\$ adj3 (cancer\$ or neoplasm\$ or neoplasia or tumour\$ or tumor\$ or carcinoma or adenocarcinoma or malingnan\$ or metasta\$)).mp.	5226
30	or/26-29	5226
31	exp vulva cancer/	4314
32	exp Vulvar Neoplasms/	6076
33	(vulv\$ adj3 (cancer\$ or neoplasm\$ or neoplasia or tumour\$ or tumor\$ or carcinoma or adenocarcinoma or malingnan\$ or metasta\$)).mp.	7709
34	or/31-33	7709
35	exp Anus Neoplasms/	5996
36	exp Anal Cancer/	4824
37	((anus or anal) adj3 (cancer\$ or neoplasm\$ or neoplasia or tumour\$ or tumor\$ or carcinoma or adenocarcinoma or malingnan\$ or metasta\$)).mp.	7593
38	or/35-37	7593
39	exp Penile Neoplasms/	4393
40	exp Penile Cancer/	3207
41	exp Penis Cancer/	3207
42	(peni\$ adj3 (cancer\$ or neoplasm\$ or neoplasia or tumour\$ or tumor\$ or carcinoma or adenocarcinoma or malingnan\$ or metasta\$)).mp.	5138
43	or/39-42	5138
44	exp Verruca/	6051
45	exp Condylomata Acuminata/	5760
46	exp Genital Warts/	5760
47	exp Venereal Warts/	5760
48	(((\$genit\$ or ana\$ or ano\$ or vener\$) adj3 wart\$).mp.	3363
49	or/44-48	12757
50	HPV.tw.	36249
51	(papillomavirus or (papilloma adj virus)).tw.	34754
52	(VPH or HPV).mp.	37457
53	exp papillomaviridae/	40803
54	exp Papilloma/	5487
55	exp Papillomatosis/	2211

56	papilloma\$.mp.	57999
57	or/50-56	69147
58	exp Epidemiologic Studies/	2097744
59	exp prevalence/	471986
60	exp incidence/	288354
61	((epidem* or preval* or inciden*) adj3 (papilloma or papiloma or VPH or HPV)).tw.	4480
62	(epidem\$ or preval\$ or inciden\$).mp.	1903450
63	epidemiologic studies/	101787
64	("prevalence study" or "incidence study" or "prevalence studies" or "incidence studies" or "transversal studies" or "transversal study").mp.	8030
65	Or/58-64	2980618
66	Economics/	186311
67	"costs and cost analysis"/	35848
68	Cost allocation/	37719
69	Cost-benefit analysis/	65366
70	Cost control/	49429
71	Cost savings/	46549
72	Cost of illness/	16046
73	Cost sharing/	37719
74	"deductibles and coinsurance"/	37719
75	Medical savings accounts/	37719
76	Direct service cost/	140847
77	Health care costs/	119800
78	Drug costs/	59589
79	Employer health costs/	140847
80	Hospital costs/	15386
81	Health expenditures/	131486
82	Capital expenditures/	140847
83	Value of life/	90927
84	exp economics, hospital/	605243
85	cost effectiveness analys\$.mp.	110587
86	exp economics, medical/	605243
87	Economics, nursing/	20884

88	Economics, pharmaceutical/	6112
89	exp "fees and charges"/	29478
90	exp budgets/	20250
91	(low adj cost).mp.	33986
92	(economic\$ and (evaluat\$ or analys\$ or model\$)).mp.	186571
93	(high adj cost).mp.	10523
94	(health?care adj cost\$).mp.	9368
95	(fiscal or funding or financial or finance).tw.	113259
96	cost benefit analys\$.mp.	66900
97	(cost adj estimate\$).mp.	2169
98	(cost adj variable).mp.	43
99	economics, pharmaceutical/	6112
100	(unit adj cost\$).mp.	2769
101	(pharmaco adj economic\$).mp.	529
102	health economic\$.mp.	26788
103	economic aspect\$.mp.	63938
104	(cba or cea or cua).mp.	32404
105	(econom\$ or cost\$ or pric\$ or pharmacoeconomic\$).mp.	1024748
106	cost minimi?ation analys\$.mp.	3012
107	(cost\$ or (cost\$ adj2 (effective\$ or utili\$ or benefit\$ or minimi\$ or stud\$ or effic\$ or effect\$))).mp.	694616
108	cost utili\$ analys\$.mp.	7178
109	cost utili\$ analys\$.mp.	7178
110	cost of illness.mp.	16949
111	economics, nursing/	20884
112	exp economics, medical/	605243
113	exp economics, hospital/	605243
114	(economic\$ or pharmacoeconomic\$ or price\$ or pricing).tw.	234500
115	or/66-114	1339092
116	diagnos\$.ti,ab,hw.	2712910
117	guideline.ti,ab,pt,xm.	48225
118	guideline\$.ti,ab.	318106
119	consensus.ti,ab,pt,xm.	140820

120	consen\$.ti,ab.	236515
121	patient held record.mp.	50
122	exp Medical Records/	146930
123	critical pathways/ or patient selection/ or point-of-care systems/	95624
124	exp professional-patient relations/ or nurse-patient relations/	558862
125	exp clinical pathway/	6784
126	exp clinical protocol/	73922
127	exp consensus development conference/	9917
128	exp consensus development conferences as topic/	9917
129	critical pathways/	6784
130	guidelines as topic/	246604
131	exp practice guideline/	353313
132	practice guidelines as topic/	246644
133	health planning guidelines/	65603
134	(standards or guideline or guidelines).ti.	84541
135	(position statement* or policy statement* or practice parameter* or best practice*).ti,ab.	25525
136	(guideline or practice guideline or consensus development conference or consensus development conference, NIH).ti,ab.	48715
137	((practice or treatment*) adj guideline*).ab.	26706
138	(CPG or CPGs).ti.	5442
139	consensus*.ti.	18797
140	consensus*.ab. /freq=2	20196
141	((critical or clinical or practice) adj2 (path or paths or pathway or pathways or protocol*)).ti,ab.	18902
142	recommendat*.ti.	30538
143	(care adj2 (standard or path or paths or pathway or pathways or map or maps or plan or plans)).ti,ab.	52721
144	(algorithm* adj2 (screening or examination or test or tested or testing or assessment* or diagnosis or diagnoses or diagnosed or diagnosing)).ti,ab.	6078
145	(algorithm* adj2 (pharmacotherap* or chemotherap* or chemotreatment* or therap* or treatment* or intervention*)).ti,ab.	8643
146	exp prescriptions/	120952
147	exp diagnosis/	3941493
148	or/116-147	6121977
149	(Spanish or spain or espagne or espana or spagna or spanien or iberia\$.in,hw,mp.	625499
150	(catalunya or catalonia or catalogne or cataluna or catala or barcelon\$ or tarragona or lleida or lerida or girona or gerona or sabadell or hospitalet or \$hospitalet or (Valencia\$ or castello\$ or alacant or alicant\$)).in,hw,mp.	243072
151	(Murcia or (cartagen\$ not indias) or (andalu\$ or sevilla\$ or granad\$ or huelva or almeria or cadiz or jaen or malaga or (cordoba not argentin\$)) or (extremadura or caceres or badajoz or madrid) or	332719

	(castilla or salamanca or zamora or valladolid or segovia or soria or palencia or avila or burgos) or (leon not (france or clermont or rennes or lyon or USA or mexic\$))).in,hw,mp.	
	(galicia or gallego or compostela or vigo or corun\$ or ferrol or orense or ourense or pontevedra or lugo or (oviedo or gijon or asturia\$) or (cantabr\$ or santander) or (vasco or euskadi or basque or bilbao or bilbo or donosti\$ or san sebastian or vizcaya or bizkaia or guipuzcoa or gipuzkoa or alava or araba or vitoria or gasteiz) or (navarr\$ or nafarroa or pamplona or iruna or irunea) or (logron\$ or rioj\$) or (aragon\$ or zaragoza or teruel or huesca)).in,hw,mp.	174272
152		
153	(mancha or ciudad real or albacete or cuenca or (toledo not (ohio or us or usa or OH)) or (guadalajara not mexic\$) or (balear\$ or mallorca or menorca or lbiza or eivissa) or (palmas or lanzarote or canari\$ or tenerif\$) or (ceuta or melilla) or ((osasunbide\$ or osakidetza or insalud or sergas or catsalut or sespa or osasunbidea or imsalud or sescam or ib) adj1 salud)).in,hw,mp.	50091
154	or/149-153	727170
155	6 and 57 and 65 and 154	547
156	6 and 115 and 154	368
157	6 and 57 and 148 and 154	659
158	or/155-157	1054
159	15 and 57 and 65 and 154	132
160	15 and 115 and 154	221
161	15 and 57 and 148 and 154	142
162	or/159-161	407
163	25 and 57 and 65 and 154	636
164	25 and 115 and 154	391
165	25 and 57 and 148 and 154	765
166	or/163-165	1198
167	30 and 57 and 65 and 154	46
168	30 and 115 and 154	14
169	30 and 57 and 148 and 154	46
170	or/167-169	62
171	34 and 57 and 65 and 154	50
172	34 and 115 and 154	16
173	34 and 57 and 148 and 154	57
174	or/171-173	77
175	38 and 57 and 65 and 154	83
176	38 and 115 and 154	24
177	38 and 57 and 148 and 154	78
178	or/175-177	106
179	43 and 57 and 65 and 154	57
180	43 and 115 and 154	16

181	43 and 57 and 148 and 154	40
182	or/179-181	71
183	49 and 57 and 65 and 154	137
184	49 and 115 and 154	57
185	49 and 57 and 148 and 154	157
186	or/183-185	229
187	158 or 162 or 166 or 170 or 174 or 178 or 182 or 186	1662
188	limit 187 to ((english or spanish) and yr="1995 -Current")	1673

Tabla III. Estrategia de búsqueda – EBM Reviews.

Bases de datos: EBM Reviews – *Cochrane Database of Systematic Reviews* 2005 a

Septiembre de 2015

Plataforma de búsqueda: OvidSP

Fecha de búsqueda: 30 de Noviembre de 2015

Límite temporal: 1995 a actualidad

#	Término de búsqueda	Hits
1	[Cervical Cancer] {Including Limited Related Terms}	37
2	[Cervical Neoplasms] {Including Limited Related Terms}	37
3	[Cervix Cancer] {Including Limited Related Terms}	37
4	[Cervix Neoplasm] {Including Limited Related Terms}	37
5	[Uterine Cervical Cancer] {Including Limited Related Terms}	171
6	[cervix neoplasia] {Including Limited Related Terms}	623
7	((cervi\$ or uter\$) adj3 (cancer\$ or neoplasm\$ or neoplasia or tumour\$ or tumor\$ or carcinoma or adenocarcinoma or malingnan\$ or metasta\$)).mp.	192
8	or/1-7	798
9	[Head and Neck Neoplasms] {Including Limited Related Terms}	194
10	[Head and Neck Cancer] {Including Limited Related Terms}	194
11	[Head Cancer] {Including Limited Related Terms}	16
12	[neck cancer] {Including Limited Related Terms}	15
13	[Oropharyngeal Neoplasms] {Including Limited Related Terms}	4
14	[Oropharyngeal Cancer] {Including Limited Related Terms}	5
15	[Oropharynx Cancer] {Including Limited Related Terms}	5
16	[oropharynx neoplasia] {Including Limited Related Terms}	575
17	[head and neck neoplasia] {Including Limited Related Terms}	117
18	((head\$ or neck\$ or oro\$ \$pharyn\$) adj3 (cancer\$ or neoplasm\$ or neoplasia or tumour\$ or tumor\$ or carcinoma or adenocarcinoma or malingnan\$ or metasta\$)).mp.	155
19	or/9-18	775
20	((precancer\$ or pre-cancer\$ or neoplas\$ or dysplasia or lesion\$ or premalignan\$ or malignan\$ or cancer\$ or carcinoma\$ or intraepithelial) adj3 (cervi\$ or vulva\$ or vagina\$ or peni\$ or anal or anus)).mp.	253

21	(cin or cin2* or cin3* or cin1* or VAIN or VAIN1* or VAIN2* or VAIN3* or VIN or VIN1* or VIN2* or VIN3* or PeIN or PeIN1* or PeIN2* or PeIN3* or AIN or AIN1* or AIN2* or AIN3*).tw.	50
22	((precancer\$ or pre-cancer\$ or dysplasia or premalignan\$ or intraepithelial) adj3 lesion\$).mp.	45
23	[precancerous lesion] {Including Limited Related Terms}	23
24	[precancerous lesions] {Including Limited Related Terms}	138
25	[vulvar intraepithelial neoplasia] {Including Limited Related Terms}	3
26	[vaginal intraepithelial neoplasia] {Including Limited Related Terms}	0
27	[anal intraepithelial neoplasia] {Including Limited Related Terms}	1
28	[penile intraepithelial neoplasia] {Including Limited Related Terms}	0
29	[cervical intraepithelial neoplasia] {Including Limited Related Terms}	9
30	[uterine cervical neoplasms] {Including Limited Related Terms}	31
31	or/20-30	401
32	[Vaginal Neoplasm] {Including Limited Related Terms}	1
33	[vagina neoplasm] {Including Limited Related Terms}	752
34	[vagina neoplasia] {Including Limited Related Terms}	768
35	[vaginal neoplasia] {Including Limited Related Terms}	768
36	(vagin\$ adj3 (cancer\$ or neoplasm\$ or neoplasia or tumour\$ or tumor\$ or carcinoma or adenocarcinoma or malingnan\$ or metasta\$)).mp.	37
37	or/32-36	775
38	[vulva cancer] {Including Limited Related Terms}	9
39	[Vulvar Neoplasms] {Including Limited Related Terms}	8
40	[Vulva neoplasia] {Including Limited Related Terms}	574
41	[vulvar neoplasia] {Including Limited Related Terms}	575
42	(vulv\$ adj3 (cancer\$ or neoplasm\$ or neoplasia or tumour\$ or tumor\$ or carcinoma or adenocarcinoma or malingnan\$ or metasta\$)).mp.	26
43	or/38-42	578
44	[Anus Neoplasms] {Including Limited Related Terms}	2
45	[Anal Cancer] {Including Limited Related Terms}	2
46	[anus neoplasia] {Including Limited Related Terms}	674
47	[anal neoplasia] {Including Limited Related Terms}	672
48	((anus or anal) adj3 (cancer\$ or neoplasm\$ or neoplasia or tumour\$ or tumor\$ or carcinoma or adenocarcinoma or malingnan\$ or metasta\$)).mp.	43
49	or/44-48	684
50	[Penile Cancer] {Including Limited Related Terms}	1

51	[Penis Cancer] {Including Limited Related Terms}	1
52	[penis neoplasia] {Including Limited Related Terms}	579
53	[penile neoplasia] {Including Limited Related Terms}	579
54	(peni\$ adj3 (cancer\$ or neoplasm\$ or neoplasia or tumour\$ or tumor\$ or carcinoma or adenocarcinoma or malingnan\$ or metasta\$)).mp.	8
55	or/50-54	587
56	[Verruca] {Including Limited Related Terms}	10
57	[Condylomata Acuminata] {Including Limited Related Terms}	4
58	[Genital Warts] {Including Limited Related Terms}	7
59	[Venereal Warts] {Including Limited Related Terms}	7
60	(((\$genit\$ or ana\$ or ano\$ or vener\$) adj3 wart\$).mp.	20
61	or/56-60	26
62	HPV.tw.	59
63	(papillomavirus or (papilloma adj virus)).tw.	64
64	(VPH or HPV).mp.	59
65	[papillomaviridae] {Including Limited Related Terms}	1
66	[Papilloma] {Including Limited Related Terms}	3
67	[Papillomatosis] {Including Limited Related Terms}	2
68	[Human papillomavirus] {Including Limited Related Terms}	11
69	[human papilloma virus] {Including Limited Related Terms}	11
70	papilloma\$.mp.	75
71	[papilloma] {Including Limited Related Terms}	3
72	[papillomavirus] {Including Limited Related Terms}	15
73	or/62-72	80
74	[epidemiologic studies] {Including Limited Related Terms}	19
75	[prevalence] {Including Limited Related Terms}	239
76	[incidence] {Including Limited Related Terms}	807
77	((epidem* or preval* or inciden*) adj3 (papilloma or papiloma or VPH or HPV)).tw.	19
78	(epidem\$ or preval\$ or inciden\$).mp.	6835
79	("prevalence study" or "incidence study" or "prevalence studies" or "incidence studies" or "transversal studies" or "transversal study").mp.	137
80	or/74-79	6835

81	[Economics] {Including Limited Related Terms}	255
82	[pharmacoeconomics] {Including Limited Related Terms}	2
83	pharmacoeconomic\$.mp.	31
84	health economic\$.mp.	344
85	economic aspect\$.mp.	27
86	economic\$.mp.	2472
87	economic evaluation.mp.	396
88	(economic\$ and (evaluat\$ or analys\$ or model\$)).mp.	2471
89	cost utili\$ analys\$.mp.	54
90	(cost\$ or (cost\$ adj2 (effective\$ or utili\$ or benefit\$ or minimi\$ or stud\$ or effic\$ or effect\$))).mp.	5042
91	cost of illness.mp.	21
92	cost minimi?ation analys\$.mp.	10
93	cost effectiveness analys\$.mp.	266
94	cost benefit analys\$.mp.	160
95	(cba or cea or cua).mp.	307
96	(cost\$ adj3 estimate\$).mp.	513
97	(unit adj3 cost\$).mp.	91
98	budget\$.mp.	150
99	expenditure\$.mp.	375
100	(decision adj2 (tree\$ or analys\$ or model\$)).mp.	215
101	markov\$.mp.	80
102	or/81-101	5611
103	diagnos\$.ti,ab.	915
104	guideline\$.ti,ab.	370
105	consensus.ti,ab,pt.	330
106	consen\$.ti,ab.	347
107	patient held record.mp.	5
108	[Medical Records] {Including Limited Related Terms}	17
109	professional-patient relations or nurse-patient relations {Including Limited Related Terms}	14
110	critical pathways or patient selection or point-of-care systems {Including Limited Related Terms}	6

111	[clinical pathway {Including Limited Related Terms}	9
112	[clinical pathway] {Including Limited Related Terms}	9
113	[clinical protocol] {Including Limited Related Terms}	9
114	(standards or guideline or guidelines).ti.	11
115	(position statement* or policy statement* or practice parameter* or best practice*).ti,ab.	20
116	(guideline or practice guideline or consensus development conference or consensus development conference, NIH).ti,ab.	31
117	((practice or treatment*) adj guideline*).ab.	47
118	consensus*.ti.	1
119	((critical or clinical or practice) adj2 (path or paths or pathway or pathways or protocol*)).ti,ab.	17
120	recommenda*.ti.	2
121	(care adj2 (standard or path or paths or pathway or pathways or map or maps or plan or plans)).ti,ab.	270
122	(algorithm* adj2 (screening or examination or test or tested or testing or assessment* or diagnosis or diagnoses or diagnosed or diagnosing)).ti,ab.	4
123	(algorithm* adj2 (pharmacotherap* or chemotherap* or chemotreatment* or therap* or treatment* or intervention*)).ti,ab.	2
124	[prescriptions] {Including Limited Related Terms}	4098
125	[diagnosis] {Including Limited Related Terms}	1224
126	or/103-125	5253
127	(Spanish or spain or espagne or espana or spagna or spanien or iberia\$).mp.	976
128	(catalunya or catalonia or catalogne or cataluna or catala or barcelon\$ or tarragona or lleida or lerida or girona or gerona or sabadell or hospitalet or \$hospitalet or (Valencia\$ or castello\$ or alacant or alicant\$)).mp.	170
129	(Murcia or (cartagen\$ not indias) or (andalu\$ or sevilla\$ or granad\$ or huelva or almeria or cadiz or jaen or malaga or (cordoba not argentin\$)) or (extremadura or caceres or badajoz or madrid) or (castilla or salamanca or zamora or valladolid or segovia or soria or palencia or avila or burgos) or (leon not (france or clermont or rennes or lyon or USA or mexic\$))).mp.	282
130	(galicia or gallego or compostela or vigo or corun\$ or ferrol or orense or ourense or pontevedra or lugo or (oviedo or gijon or asturia\$) or (cantabr\$ or santander) or (vasco or euskadi or basque or bilbao or bilbo or donosti\$ or san sebastian or vizcaya or bizkaia or guipuzcoa or gipuzkoa or alava or araba or vitoria or gasteiz) or (navarr\$ or nafarroa or pamplona or iruna or irunea) or (logron\$ or rioja\$) or (aragon\$ or zaragoza or teruel or huesca)).mp.	155
131	(mancha or ciudad real or albacete or cuenca or (toledo not (ohio or us or usa or OH)) or (guadalajara not mexic\$) or (balear\$ or mallorca or menorca or Ibiza or eivissa) or (palmas or lanzarote or canari\$ or tenerif\$) or (ceuta or melilla) or ((osasunbide\$ or osakidetza or insalud or sergas or catsalut or sespa or osasunbidea or imsalud or sescam or ib) adj1 salud)).mp.	29
132	Or/127-131	1323
133	8 or 19 or 31 or 37 or 43 or 49 or 55 or 61	1383
134	133 and 132 and 73 and 80	9
135	133 and 132 and 102	153
136	133 and 132 and 73 and 126	6
137	Or/134-136	154

Tabla IV. Prevalencia de genotipos de VPH asociados a verrugas genitales en España

Referencia	Prevalencia de VPH+ n+/total (%)	Prevalencia de los genotipos cubiertos por la vacuna tetraivalente - genotipo: %	Prevalencia de los genotipos cubiertos por la vacuna nonavalente - genotipo: %
Pera, 1999 ^{17 a}	17/21 (80,9%)	6/11: 82,3%; 16/18: 17,6%	31/33/45/52/58: ND
Zarco Olivo, 2003 ^{18 b}	41/54 (75,9%)	6: 39,0%; 11: 24,4%; 16: 14,6%; 18: 0%	31: 2,4%; 33: 2,4%; 45: 0%; 52: 0%; 58: 0%

^aEn este estudio 14 de 21 pacientes (66,7%) eran VIH+. ^bEn este estudio el 100% de los pacientes eran VIH+; ND: no determinado; VPH: Virus del Papiloma Humano

Tabla V. Prevalencia de genotipos de VPH asociados a verrugas genitales en España

Prevalencia de genotipos de VPH asociados a lesiones precancerosas de alto grado de
cérnix y ano en España

Referencia	Prevalencia de VPH+ n+/total (%)	Prevalencia de los genotipos cubiertos por la vacuna tetavalente - genotipo: %	Prevalencia de los genotipos cubiertos por la vacuna nonavalente - genotipo: %
Lesiones precancerosas de cérvix (CIN 2/3 o HSIL)			
Bernal, 2008 ^{19 a}	340/420 (80,9%)	6/11: NE; 16: 57,9%; 18: 27,6%	31: 4,4%; 33/45/52/58: NE
Cañadas, 2010 ^{20 b}	23/NE (ND%)	6: 4,3%; 11: 0%; 16: 69,6%; 18: 17,4%	31: 4,3%; 33: 34,8%; 45: 8,7%; 52: 8,7%; 58: 13,0%
Darwich, 2011 ^{21 c}	50/58 (98,0%)	6: 4,0%; 11: 0%; 16: 60,0%; 18: 6,0%	31: 6,0%; 33: 18,0%; 45: 2,0%; 52: 2,0%; 58: 10%
García-Espinosa, 2012 ²²	158/NE (ND%)	6: 3,2%; 11: 3,2%; 16: 56,3%; 18: 5,7%	31: 10,8%; 33: 8,9%; 45: 1,9%; 52: 9,5%; 58: 8,2%
García-García, 2010 ²³	214/225 (95,1%)	6: 0,9%; 11: 2,8%; 16: 49,1%; 18: 3,7%	31: 10,8%; 33: 6,0%; 45: 1,9%; 52: 0,9%; 58: 3,7%
González-Bosquet, 2008 ²⁴	187/206 (90,8%)	6/11: ND; 16: 44,9%; 18: 4,3%	31: 15,5%; 33: 8,6%; 45: 2,7%; 52: 4,8%; 58: 6,9%
Herraez-Hernandez, 2013 ²⁵	68/NE (ND%)	6: 19,1%; 11: 2,9%; 16: 69,1%; 18: 5,9%	31: 10,3%; 33: 2,9%; 45: 5,9%; 52: 11,8%; 58: 7,3%
Jerma Puertas, 2011 ²⁶	339/358 (94,7%)	6/11: 2,9%; 16: 53,1%; 18: 10,3%	31/33: 8,0%; 45: 0%; 52: 9,2%; 58: 6,1% (d)
Martin, 2011 ²⁷	79/82 (96,3%)	6: 1,3%; 11: 0%; 16: 50,6%; 18: 5,1%	31: 11,4%; 33: 10,1%; 45: 2,5%; 52: 13,9%; 58: 7,6%
Mateos Lindemann, 2010 ²⁸	205/NE (ND%)	6/11: ND; 16: 60,0%; 18: 2,4%	31: 15,1%; 33: 7,8%; 45: 2,9%; 52: 9,3%; 58: 12,2%
Mazarico, 2012 ²⁹	411/478 (86%)	6: 2,5%; 11: 1,0%; 16: 43,9%; 18: 7,3%	31: 10,7%; 33: 6,7%; 45: 2,5%; 52: 4,4%; 58: 8,5%
Nicolau, 2014 ³⁰	46/75 (61,3%)	6: 15,2%; 11: 0%; 16: 54,3%; 18: 34,8%	31: 6,5%; 33: 10,9%; 45: 6,5%; 52: 4,3%; 58: 8,7%
Otero-Motta, 2011 ³¹	183/NE (ND%)	6: 13,1%; 11: 2,7%; 16: 46,4%; 18: 3,8%	31: 9,8%; 33: 13,1%; 45: 1,1%; 52: 3,3%; 58: 15,3%
Selva, 2009 ³²	195/226 (86,2%)	6: 4,1%; 11: 2,0%; 16: 50,8%; 18: 5,6%	31: 12,8%; 33: 7,7%; 45: 1,5%; 52: 5,1%; 58: 7,2%
Lesiones precancerosas de ano (AIN 2/3 o HSIL)			
Darwich, 2012 ^{33 b}	30/NE (ND%)	6: 33,3%; 11: 23,3%; 16: 43,3%; 18: 16,7%	31: 3,3%; 33: 36,7%; 45: 23,3%; 52: 23,3%; 58: 36,7%
García-Espinosa, 2013 ^{34 b}	20/NE (ND%)	6: 30,0%; 11: 15,0%; 16: 50,0%; 18: 10,0%	31: 30,0%; 33: 20,0%; 45: 10,0%; 52: 30,0%; 58: 35,0%
Hidalgo-Tenorio, 2014 ^{35 b}	28/NE (ND%)	6: 25,0%; 11: 21,4%; 16: 39,3%; 18: 21,4%	31/33/45/52/58: NE
Sirera, 2013 ^{36 b}	58/69 (84,1%)	6: 20,7%; 11: 3,4%; 16: 65,5%; 18: 25,9%	31: NE; 33: 34,5%; 45/52: NE; 58: 41,4%

Torres, 2013 ³⁷ ^b	43/44 (97,7%)	6: 34,1%; 11: 11,4%; 16: 59,1%; 18: 15,9%	31: 27,3%; 33: 18,2%; 45: 22,7%; 52: 29,5%; 58: 20,5%
---	---------------	--	---

^aEn el artículo original las prevalencias para CIN2 y CIN3 se proporcionan separadamente, aunque en la tabla se presentan conjuntamente.

^bTodos los pacientes del estudio eran VIH+. ^cEn este estudio 17 de 51 pacientes (33,3%) eran VIH+. En el artículo original los datos de prevalencias se proporcionan separadamente para pacientes VIH+/-, aunque en la tabla se presentan conjuntamente. ^dLos genotipos 52 y 58 sólo fueron determinados en 97 de los pacientes. AIN 2/3: Neoplasia Intraepitelial de Ano de grado 2 o 3; CIN 2/3: Neoplasia Intraepitelial de Cérvix de grado 2 o 3; HSIL: lesión precancerosa de alto grado; ND: No Determinado; NE: No Especificado; VIH: Virus de la Inmunodeficiencia Humana; VPH: Virus del Papiloma Humano.

Tabla VI. Prevalencia de genotipos de VPH asociados a cáncer de cérvix, vulva, vagina pene, ano y cabeza y cuello y lesiones precancerosas de pene en España

Referencia	Prevalencia de VPH+ n+/total (%)	Prevalencia de los genotipos cubiertos por la vacuna tetraivalente - genotipo: (%)	Prevalencia de los genotipos cubiertos por la vacuna nonavalente - genotipo: (%)
Cáncer de cérvix			
Alemany, 2012 ³⁹	904/1.043 (86,7%)	6: 0,2%; 11: 0%; 16: 66,5%; 18: 5,9%	31: 3,4%; 33: 5,8%; 45: 3,4%; 52: 2,2%; 58: 1,1%
Bernal, 2008 ¹⁹	56/60 (93,3%)	6: 0%; 11: 0%; 16: 90%; 18: 8%	31: 0%; 33/45/52/58: NE
Bosch, 1995 ⁴⁰	43/46 (93,5%)	6/11: NE; 16: 58,1%; 18: 7,0%	31: 7,0%; 33: NE; 45: 4,6%; 52: NE; 58: 2,3%
Darwich, 2011 ^{21 a}	83/85 (97,6%)	6: 1,2%; 11: 0%; 16: 79,5%; 18: 3,6%	31: 0%; 33: 6,0%; 45: 1,2%; 52: 4,8%; 58: 3,6%
Martro, 2012 ⁴¹	70/73 (95,9%)	6: 1,4%; 11: 0%; 16: 61,4%; 18: 8,6%	31: 8,6%; 33: 7,1%; 45: 2,9%; 52: 8,6%; 58: 1,4%
Mazarico, 2012 ²⁹	32/37 (87%)	6: 5,4%; 11: 0%; 16: 48,6%; 18: 8,1%	31: 10,8%; 33: 2,7%; 45: 8,1%; 52: 8,1%; 58: 0%
Cáncer de vulva			
Alonso, 2011 ⁴²	19/98 (19,4%)	6: ND%; 11: ND%; 16: 73,7%; 18: 0%	31: 5,3%; 33: 10,5%; 45: 0%; 52: 5,3%; 58: 0%
Guerrero, 2011 ⁴³	5/30 (16,7%)	6: 20%; 11: 0%; 16: 20%; 18: 20%	31: 0%; 33: 0%; 45: 0%; 52: 0%; 58: 0%
Santos, 2006 ^{44 b}	16/92 (17,4%)	6: 12,5%; 11: 0%; 16: 75,0%; 18: 0%	31: 6,2%; 33: 12,5%; 45: 0%; 52: 0%; 58: 0%
Cáncer de vagina			
Alonso, 2012 ⁴⁵	40/57 (70,2%)	6: 0%; 11: 0%; 16: 67,5%; 18: 5,0%	31: 5,0%; 33: 7,5%; 45: 0%; 52: 5,0%; 58: 5,0%
Fuste, 2010 ⁴⁶	25/32 (78,1%)	6: 0%; 11: 0%; 16: 72,0%; 18: 0%	31: 0%; 33: 0%; 45: 0%; 52: 8,0%; 58: 4,0%
Cáncer de pene			
Ferrandiz-Pulido, 2013 ^{38 c}	31/77 (40,2%)	6: 6,4%; 11: 0%; 16: 80,6%; 18: 0%	31: 0%; 33: 3,2%; 45: 3,2%; 52: 0%; 58: 3,2%
Guerrero, 2008 ⁴⁷	11/24 (45,8%)	6: 0%; 11: 0%; 16: 90,9%; 18: 0%	31: 0%; 33: 0%; 45: 0%; 52: 0%; 58: 0%
Masferrer, 2012 ⁴⁸	32/79 (40,5%).	6: 6,2%; 11: 0%; 16: 78,1%; 18: 0%	31: 0%; 33: 6,2%; 45: 3,1%; 52: 0%; 58: 6,2%
García-de Marcos, 2014 ⁴⁹	16/61 (26,2%)	6/11: ND; 16: 12,5%; 18: 31,2%	31: 0%; 33: 0%; 45: 0%; 52: 0%; 58: 0%

Llamas-Martinez, 2008 ⁵⁰	14/33 (42,4%)	6: 76,9%; 11: 0%; 16: 84,6%; 18: 0%	31: 23,1%; 33: 0%; 45: 0%; 52: 0%; 58: ND%
--	---------------	---	---

^a En este estudio 13 de 85 pacientes (15,3%) eran VIH+. En el artículo original los datos de prevalencias se proporcionan separadamente para pacientes VIH+/-, aunque en la tabla se presentan conjuntamente. ^b Se han incluido las prevalencias estimadas a partir de la técnica SPF-10. ^c De los 77 pacientes incluidos en el estudio, 67 presentaban cáncer de pene y 10 presentaban PIN. Las prevalencias de VPH fueron del 32,8% y del 90% en los casos de cáncer de pene y PIN, respectivamente. Los porcentajes de genotipos hacen referencia al total de la muestra